Auf dieser Seite
CMPS COMPASS Pathways Plc - American Depository Shares
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 5, 2026
$11,90
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$4,8852-Wochen-Tief
$15,8752-Wochen-Hoch
Marktkapitalisierung (MRQ)
$1.62B
P/E
-3.9
EPS
$-3.08
Ihre Abzeichen
52W-Spanne
$5–$16
Analystenbewertung
BUY
Kursziel
$24
P/E
-3.9
ROE
-524.8%
Nettogewinnmarge
·
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
CMPS Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$11.90
Marktkapitalisierung (MRQ)
$1.62B
P/E
-3.9
EPS
$-3.08
ROE
-524.8%
Verschuldungsgrad (MRQ)
0.6
52W-Spanne
$5–$16
CMPS Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Über COMPASS Pathways Plc - American Depository Shares Unternehmensübersicht von Wikipedia
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin (COMP360), has completed phase 3 clinical trials for treatment-resistant depression. The results showed clear benefit to participants as measured on the MADRS depression rating scale. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration (FDA). It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine (MDMA).
Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder (PTSD) New Drug Application (NDA), Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus.
Compass Pathways has entered partnerships with several independent psychedelic academic scientists, including Jason Wallach, Hamilton Morris, and Adam Halberstadt among others, to develop novel psychedelic drugs for potential medical use. Wallach's lab is said to have sought patents for over 200 novel compounds as of May 2024.
Compass Pathways switched from being a nonprofit organization to a for-profit company in 2016. The pharmaceutical company has been backed and funded by a number of tech entrepreneurs such as Peter Thiel. The media outlet Sifted remarks that the biotech billionaire Christian Angermayer was instrumental in the founding of Compass Pathways."
Quelle: Wikipedia (Englisch), CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
SektorHealthcare
BrancheBiotechnology
Mitarbeiter156
LandGB
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
EPS$-3.082019-12-31 → 2025-12-31
Freier Cashflow·2021-12-31 → 2024-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | CMPS | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E | -3.95-Jahres-Durchschnitt ≈-4.7 | ≈-4.7 | · | · | |
| K/B (MRQ) | 19.1 | · | 6.8 | Überbewertet | |
| EV / EBITDA | -5.7 | · | · | · | |
| Price / Cash Flow (Kurs / Cashflow) | -7.3 | · | · | · | |
| Price / Tangible Book (Kurs / Materieller Buchwert) | 2.9 | · | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | CMPS | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| ROA | -135.8%5-Jahres-Durchschnitt ≈-62.9% | ≈-62.9% | -5.4% | Schwach | |
| ROE | -524.8%5-Jahres-Durchschnitt ≈-147.3% | ≈-147.3% | -9.2% | Schwach | |
| ROIC | 836.7%5-Jahres-Durchschnitt ≈117.6% | ≈117.6% | -17.1% | Spitzenklasse |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | CMPS | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital (MRQ) | 0.6 | · | · | · | |
| Liquiditätsgrad (MRQ) | 1.35-Jahres-Durchschnitt ≈10.4 | ≈10.4 | 4.5 | Geringe Liquidität | |
| Quick Ratio | 0.65-Jahres-Durchschnitt ≈8.8 | ≈8.8 | 3.2 | Geringe Liquidität | |
| Langfristige Schulden / Eigenkapital (MRQ) | 0.6 | · | · | · |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Für diese Kennzahlengruppe sind noch keine Daten verfügbar
Noch nicht genügend Fundamentaldaten vorhanden, um diese Kennzahlengruppe zu berechnen.
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Für diese Kennzahlengruppe sind noch keine Daten verfügbar
Noch nicht genügend Fundamentaldaten vorhanden, um diese Kennzahlengruppe zu berechnen.
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
-103.4%
Nächster Bericht
Nov 02, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Jul 29, 2026 | $-1.88 | $-0.41 | -364.1% |
| 31. März 2026 | Mai 13, 2026 | $-0.30 | $-0.39 | 22.2% |
| 31. Dezember 2025 | $-1.00 | $-0.40 | -148.6% | |
| 30. September 2025 | $-1.44 | $-0.40 | -262.0% | |
| 30. Juni 2025 | $-0.41 | $-0.44 | 6.1% | |
| 31. März 2025 | $-0.38 | $-0.48 | 20.4% | |
| 31. Dezember 2024 | $-0.63 | $-0.64 | 2.3% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| R&D Expense | $118M | $119M | $88M | $65M | $44M | $23M | |
| SG&A Expense | $61M | $59M | $49M | $45M | $39M | $28M | |
| Operating Expenses | $179M | $178M | $137M | $110M | $83M | $51M | |
| Operating Income | $-179M | $-178M | $-137M | $-110M | $-83M | $-51M | |
| Interest Expense | · | · | $2M | $0 | $0 | · | |
| Interest Income | $7M | $8M | $5M | · | · | · | |
| Other Non-op | $1M | $823.0K | $255.0K | $19M | $12M | $-9M | |
| Pretax Income | $-290M | $-154M | $-118M | $-91M | $-72M | $-60M | |
| Income Tax | $-2M | $2M | $780.0K | $408.0K | $199.0K | $32.0K | |
| Net Income | $-288M | $-155M | $-118M | $-92M | $-72M | $-60M | |
| EPS (Basic) | $-3.08 | $-2.30 | $-2.32 | $-2.16 | $-1.79 | $-3.55 | |
| EPS (Diluted) | $-3.08 | $-2.30 | $-2.32 | $-2.16 | $-1.79 | $-3.55 | |
| Shares (Basic) | 93,504,836 | 67,482,902 | 51,028,024 | 42,436,292 | 39,997,587 | 16,991,664 | |
| Shares (Diluted) | 93,504,836 | 67,482,902 | 51,028,024 | 42,436,292 | 39,997,587 | 16,991,664 | |
| EBITDA | $-179M | $-178M | $-137M | $-110M | $-83M | · |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $150M | $165M | $220M | $143M | $273M | $190M | |
| Prepaid Expense | $42M | $36M | $41M | $48M | $22M | $12M | |
| Other Current Assets | $6M | $4M | $2M | $1M | $1M | $509.0K | |
| Current Assets | $191M | $201M | $261M | $192M | $295M | $202M | |
| PP&E (Net) | · | $189.0K | $423.0K | $617.0K | $398.0K | $245.0K | |
| PP&E (Gross) | · | · | · | $1M | $756.0K | $433.0K | |
| Accum. Depreciation | · | · | · | $530.0K | $358.0K | $188.0K | |
| Other Non-current Assets | $12M | $7M | $7M | $1M | $213.0K | $57.0K | |
| Total Assets | $210M | $214M | $276M | $197M | $301M | $203M | |
| Accounts Payable | $15M | $12M | $6M | $5M | $3M | $3M | |
| Current Liabilities | $248M | $34M | $20M | $16M | $15M | $7M | |
| Capital Leases | $1M | $303.0K | $2M | $418.0K | $1M | · | |
| Total Liabilities | $263M | $59M | $50M | $16M | $16M | $7M | |
| Long-term Debt | $32M | $30M | $29M | $0 | · | · | |
| Total Debt | $32M | $30M | · | · | · | · | |
| Common Stock | $973.0K | $702.0K | $635.0K | · | · | · | |
| Paid-in Capital | $784M | $705M | $622M | $459M | $445M | $279M | |
| Retained Earnings | $-823M | $-535M | $-380M | $-261M | $-170M | $-98M | |
| AOCI | $-15M | $-16M | $-17M | $-17M | $9M | $15M | |
| Stockholders' Equity | $-53M | $155M | $226M | $181M | $284M | $197M | |
| Liabilities + Equity | $210M | $214M | $276M | $197M | $301M | $203M | |
| Shares Outstanding | 96,085,785 | 68,552,215 | 61,943,471 | · | · | · |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| D&A | · | · | $242.0K | $330.0K | $175.0K | $112.0K | |
| Stock-based Comp | $14M | $20M | $17M | $13M | $9M | $18M | |
| Deferred Tax | $22.0K | $-437.0K | $-1M | $-1M | $-545.0K | $-221.0K | |
| Other Non-cash | · | · | $5M | $-26M | $-4M | · | |
| Operating Cash Flow | $-157M | $-119M | $-97M | $-105M | $-68M | $-41M | |
| CapEx | · | $0 | $66.0K | $596.0K | $334.0K | $131.0K | |
| Investing Cash Flow | · | $0 | $-64.0K | $-596.0K | $-334.0K | $-628.0K | |
| Debt Issued | · | $0 | $30M | $0 | $0 | · | |
| Net Debt Issued | · | $0 | $30M | · | · | · | |
| Stock Issued | $140M | $26M | $145M | $440.0K | $155M | $0 | |
| Net Stock Activity | $140M | $26M | $145M | $440.0K | $155M | · | |
| Financing Cash Flow | $141M | $64M | $174M | $1M | $157M | $194M | |
| Net Change in Cash | $-15M | $-55M | $77M | $-130M | $83M | $165M | |
| Taxes Paid | $755.0K | · | · | · | · | · | |
| Free Cash Flow | · | $-119M | $-97M | $-106M | $-68M | · | |
| Levered FCF | · | · | $-100M | · | · | · |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| ROA | -135.8% | -63.4% | -50.1% | -36.7% | -28.4% | · | |
| ROE | -524.8% | -89.2% | -49.5% | -48.7% | -24.3% | · | |
| ROIC | 836.7% | -97.4% | -61.1% | -61.2% | -29.3% | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 0.8 | 5.9 | 13.3 | 12.3 | 19.5 | · | |
| Quick Ratio | 0.6 | 4.9 | 11.2 | 9.2 | 18.1 | · | |
| Debt / Equity | -0.6 | 0.2 | · | · | · | · | |
| LT Debt / Equity | -0.3 | 0.2 | · | · | · | · | |
| Interest Coverage | · | · | -62.1 | · | · | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Book Value / Share | $-0.55 | $2.26 | · | · | · | · | |
| Cash Flow / Share | $-1.68 | $-1.77 | $-1.91 | $-2.48 | $-1.69 | · | |
| Cash / Share | $1.56 | $2.41 | · | · | · | · | |
| EPS (TTM) | $-3.08 | $-2.30 | $-2.32 | $-2.16 | $-1.79 | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Net Income TTM | $-288M | $-155M | $-118M | $-92M | $-72M | · | |
| Market Cap | $663M | $259M | · | · | · | · | |
| Enterprise Value | $545M | $124M | · | · | · | · | |
| P/E | -2.2 | -1.6 | -3.8 | -3.7 | -12.3 | · | |
| P/B | -12.5 | 1.7 | · | · | · | · | |
| P / Tangible Book | · | 1.7 | · | · | · | · | |
| P / Cash Flow | -4.2 | -2.2 | · | · | · | · | |
| P / FCF | · | -2.2 | · | · | · | · | |
| EV / EBITDA | -3.0 | -0.7 | · | · | · | · | |
| EV / FCF | · | -1.0 | · | · | · | · | |
| Earnings Yield | -44.6% | -60.9% | -26.5% | -26.9% | -8.1% | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $29M | $26M | $30M | $27M | $30M | $31M | $32M | $33M | $29M | $25M | $27M | $22M | $20M | $19M | $20M | $14M | |
| SG&A Expense | $23M | $16M | $16M | $13M | $13M | $19M | $16M | $15M | $14M | $14M | $11M | $13M | $13M | $13M | $12M | $12M | |
| Operating Expenses | $52M | $43M | $46M | $41M | $43M | $50M | $48M | $48M | $43M | $39M | $38M | $34M | $33M | $32M | $32M | $26M | |
| Operating Income | $-52M | $-43M | $-46M | $-41M | $-43M | $-50M | $-48M | $-48M | $-43M | $-39M | $-38M | $-34M | $-33M | $-32M | $-32M | $-26M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $1M | · | $1M | · | $0 | $0 | $0 | |
| Interest Income | $4M | $2M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $638.0K | · | · | · | |
| Other Non-op | $546.0K | $484.0K | $370.0K | $383.0K | $-176.0K | $803.0K | $337.0K | $191.0K | $167.0K | $128.0K | $-8M | $112.0K | $-11.0K | $8M | $1M | $7M | |
| Pretax Income | $-253M | $91M | $-97M | $-138M | $-38M | $-18M | $-42M | $-38M | $-38M | $-35M | $-32M | $-33M | $-28M | $-24M | $-31M | $-18M | |
| Income Tax | $331.0K | $-11.0K | $-3M | $-230.0K | $137.0K | $354.0K | $1M | $173.0K | $176.0K | $222.0K | $394.0K | $62.0K | $194.0K | $130.0K | $92.0K | $120.0K | |
| Net Income | $-254M | $91M | $-94M | $-138M | $-38M | $-18M | $-43M | $-39M | $-38M | $-35M | $-33M | $-33M | $-28M | $-24M | $-31M | $-18M | |
| EPS (Basic) | $-1.88 | $0.71 | $-1.03 | $-1.44 | $-0.41 | $-0.20 | $-0.63 | $-0.56 | $-0.56 | $-0.55 | $618.92 | $-0.67 | $-620.00 | $-0.57 | $-0.73 | $-0.43 | |
| EPS (Diluted) | $-1.88 | $-0.30 | $-0.99 | $-1.44 | $-0.41 | $-0.24 | $-0.63 | $-0.56 | $-0.56 | $-0.55 | $618.92 | $-0.67 | $-620.00 | $-0.57 | $-0.73 | $-0.43 | |
| Shares (Basic) | 135,039,810 | 110,064,581 | · | 95,337,993 | 93,341,594 | 89,192,252 | · | 68,395,343 | 68,371,139 | 64,222,178 | · | 49,633,104 | 45,565,991 | 42,725,863 | · | 42,525,855 | |
| Shares (Diluted) | 135,039,810 | 130,266,693 | · | 95,337,993 | 93,341,594 | 98,641,623 | · | 68,395,343 | 68,371,139 | 64,222,178 | · | 49,633,104 | 45,565,991 | 42,725,863 | · | 42,525,855 | |
| EBITDA | $-52M | $-43M | · | $-41M | $-43M | $-50M | · | $-48M | $-43M | $-39M | · | $-34M | $-33M | $-32M | · | $-25M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $433M | $466M | $150M | $186M | $222M | $260M | $165M | $207M | $229M | $263M | $220M | $248M | $148M | $117M | $143M | $173M | |
| Prepaid Expense | $42M | $44M | $42M | $56M | $54M | $45M | $36M | $26M | $36M | $31M | $41M | $36M | $45M | $50M | $48M | $45M | |
| Other Current Assets | $8M | $7M | $6M | $3M | $2M | $2M | $4M | $2M | $3M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | |
| Current Assets | $476M | $511M | $191M | $242M | $276M | $305M | $201M | $234M | $265M | $296M | $261M | $285M | $194M | $168M | $192M | $218M | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | $359.0K | $423.0K | $309.0K | $482.0K | $612.0K | $617.0K | $555.0K | |
| PP&E (Gross) | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $950.0K | |
| Accum. Depreciation | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $395.0K | |
| Other Non-current Assets | $20M | $14M | $12M | $5M | $9M | $8M | $7M | $7M | $6M | $6M | $7M | $6M | $7M | $212.0K | $1M | $299.0K | |
| Total Assets | $505M | $532M | $210M | $256M | $294M | $319M | $214M | $247M | $279M | $309M | $276M | $299M | $210M | $173M | $197M | $225M | |
| Accounts Payable | $12M | $11M | $15M | $5M | $11M | $9M | $12M | $8M | $8M | $9M | $6M | $4M | $2M | $4M | $5M | $20M | |
| Current Liabilities | $367M | $154M | $248M | $197M | $31M | $30M | $34M | $26M | $22M | $19M | $20M | $15M | $13M | $11M | $16M | $30M | |
| Capital Leases | $2M | $779.0K | $1M | $2M | $2M | $259.0K | $303.0K | $459.0K | $799.0K | $1M | $2M | $2M | $3M | $412.0K | $418.0K | $425.0K | |
| Total Liabilities | $420M | $205M | $263M | $218M | $131M | $124M | $59M | $54M | $52M | $50M | $50M | $46M | $43M | $12M | $16M | $30M | |
| Long-term Debt | $51M | $50M | $32M | $31M | $31M | $31M | $30M | $30M | $29M | $29M | $29M | $28M | $28M | · | $0 | · | |
| Total Debt | $51M | $50M | · | $31M | $31M | $31M | · | $28M | · | · | · | · | · | · | · | · | |
| Common Stock | $1M | $1M | $973.0K | $973.0K | $946.0K | $938.0K | $702.0K | $699.0K | $699.0K | $699.0K | $635.0K | · | · | · | · | · | |
| Paid-in Capital | $1.08B | $1.07B | $784M | $781M | $767M | $763M | $705M | $700M | $695M | $690M | $622M | $617M | $496M | $464M | $459M | $455M | |
| Retained Earnings | $-985M | $-731M | $-823M | $-729M | $-591M | $-553M | $-535M | $-491M | $-453M | $-415M | $-380M | $-347M | $-314M | $-285M | $-261M | $-230M | |
| AOCI | $-15M | $-15M | $-15M | $-15M | $-15M | $-16M | $-16M | $-17M | $-17M | $-17M | $-17M | $-17M | $-17M | $-17M | $-17M | $-31M | |
| Stockholders' Equity | $85M | $327M | $-53M | $38M | $163M | $195M | $155M | $193M | $226M | $259M | $226M | $253M | $166M | $162M | $181M | $195M | |
| Liabilities + Equity | $505M | $532M | $210M | $256M | $294M | $319M | $214M | $247M | $279M | $309M | $276M | $299M | $210M | $173M | $197M | $225M | |
| Shares Outstanding | 135,722,306 | 134,923,295 | 96,085,785 | 96,002,044 | 93,586,348 | 92,848,326 | 68,552,215 | 68,409,068 | 68,387,469 | 68,342,534 | 61,943,471 | · | · | · | · | · |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | $59.0K | $63.0K | $61.0K | · | $186.0K | $110.0K | $48.0K | $76.0K | $100.0K | |
| Stock-based Comp | $4M | $3M | $3M | $3M | $4M | $4M | $4M | $5M | $5M | $5M | $4M | $4M | $5M | $4M | $3M | $4M | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | $9M | · | · | · | $-8M | · | · | |
| Operating Cash Flow | $-40M | $-48M | $-38M | $-35M | $-39M | $-46M | $-42M | $-22M | $-34M | $-21M | $-28M | $-17M | $-25M | $-28M | $-45M | $-19M | |
| CapEx | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $18.0K | $19.0K | $29.0K | $107.0K | $-5.0K | |
| Investing Cash Flow | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $-18.0K | $-17.0K | $-29.0K | $-107.0K | $5.0K | |
| Debt Issued | $0 | $19M | · | · | $0 | $0 | · | $0 | · | · | $0 | $0 | · | · | $0 | $0 | |
| Net Debt Issued | · | $19M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Stock Issued | · | $141M | $0 | $0 | $0 | $140M | $0 | $0 | $0 | $26M | $-41.0K | $117M | $27M | $1M | $440.0K | $0 | |
| Net Stock Activity | · | $141M | · | · | · | $140M | · | · | · | $26M | · | · | · | $1M | · | · | |
| Financing Cash Flow | $8M | $362M | $187.0K | $0 | $166.0K | $140M | $155.0K | $-53.0K | $210.0K | $64M | $41.0K | $117M | $56M | $1M | $639.0K | $-1.0K | |
| Net Change in Cash | $-33M | $316M | $-36M | $-36M | $-38M | $95M | $-42M | $-22M | $-34M | $43M | $-28M | $100M | $31M | $-26M | $-30M | $-34M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-21M | · | · | · | $-28M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-22M | · | · | · | · | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -63.6% | 21.4% | · | -54.8% | -13.4% | -5.7% | · | -14.1% | -15.6% | -14.6% | · | -12.8% | -12.6% | -10.9% | · | -16.4% | |
| ROE | -205.4% | 34.9% | · | -119.4% | -19.8% | -7.9% | · | -17.2% | -19.4% | -16.7% | · | -14.9% | -14.5% | -11.5% | · | -18.9% | |
| ROIC | -38.8% | -11.4% | · | -58.8% | -22.3% | -22.4% | · | -21.8% | -19.2% | -15.0% | · | -13.5% | -19.8% | -19.8% | · | -13.2% |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 3.3 | · | 1.2 | 8.8 | 10.2 | · | 8.9 | 12.0 | 15.2 | · | 18.6 | 15.2 | 14.9 | · | 7.4 | |
| Quick Ratio | 1.2 | 3.0 | · | 0.9 | 7.1 | 8.7 | · | 7.9 | 10.4 | 13.5 | · | 16.2 | 11.6 | 10.4 | · | 5.9 | |
| Debt / Equity | 0.6 | 0.2 | · | 0.8 | 0.2 | 0.2 | · | 0.1 | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.6 | 0.2 | · | 0.5 | 0.1 | 0.1 | · | 0.1 | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -35.1 | · | -31.5 | · | · | · | · |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.62 | $2.42 | · | $0.39 | $1.74 | $2.11 | · | $2.82 | $3.31 | $3.79 | · | · | · | · | · | · | |
| Cash Flow / Share | · | $-0.37 | · | · | · | $-0.46 | · | · | · | $-0.32 | · | · | · | $-0.65 | · | · | |
| Cash / Share | $3.19 | $3.45 | · | $1.94 | $2.37 | $2.80 | · | $3.03 | $3.34 | $3.85 | · | · | · | · | · | · | |
| EPS (TTM) | $-4.61 | $-3.14 | · | $-2.72 | $-1.84 | $-1.99 | · | $617.25 | $617.14 | $-2.30 | · | $-621.97 | $-621.73 | $-2.23 | · | $-2.05 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-394M | $-179M | · | $-237M | $-138M | $-138M | · | $-144M | $-139M | $-129M | · | $-117M | $-102M | $-95M | · | $-86M | |
| Market Cap | $1.92B | $746M | · | $550M | $262M | $266M | · | $431M | $413M | $569M | · | · | · | · | · | · | |
| Enterprise Value | $1.54B | $331M | · | $395M | $71M | $36M | · | $252M | · | · | · | · | · | · | · | · | |
| P/E | -3.1 | -1.8 | · | -2.1 | -1.5 | -1.4 | · | 0.0 | 0.0 | -3.6 | · | -0.0 | -0.0 | -4.5 | · | -5.2 | |
| P/B | 22.7 | 2.3 | · | 14.6 | 1.6 | 1.4 | · | 2.2 | 1.8 | 2.2 | · | · | · | · | · | · | |
| P / Tangible Book | 22.7 | 2.3 | · | 14.6 | 1.6 | 1.4 | · | 2.2 | 1.8 | 2.2 | · | · | · | · | · | · | |
| P / Cash Flow | · | -15.6 | · | · | · | -5.8 | · | · | · | -27.3 | · | · | · | · | · | · | |
| Earnings Yield | -32.6% | -56.8% | · | -47.5% | -65.7% | -69.6% | · | 9797.6% | 10217.5% | -27.6% | · | -8405.0% | -7508.8% | -22.5% | · | -19.1% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Nettoergebnis | $-288M | $-155M | $-118M | $-92M | $-72M |
| Verwässerte EPS | $-3.08 | $-2.30 | $-2.32 | $-2.16 | $-1.79 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital | -0.6 | 0.2 | · | · | · |
| Liquiditätsgrad | 0.8 | 5.9 | 13.3 | 12.3 | 19.5 |
| Quick Ratio | 0.6 | 4.9 | 11.2 | 9.2 | 18.1 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | · | $-119M | $-97M | $-106M | $-68M |
Institutionelle Eigentümer (13F) 248 Einreicher · $1.4B gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
248
Gehaltener Wert
$1.4B
Neue Positionen
65
Geschlossene Positionen
30
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 65 (+5 vs. Vorquartal) | 30 (+7 vs. Vorquartal) | 78 (+4 vs. Vorquartal) | 54 (+25 vs. Vorquartal) | -1.1M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| Deep Track Capital, LP | $172.085.168 | 12.161.496 | 12,70% | Aktien |
| RTW INVESTMENTS, LP | $151.418.782 | 10.700.974 | 11,18% | Aktien |
| BIT Capital GmbH | $89.835.478 | 6.348.797 | 6,63% | Aktien |
| TANG CAPITAL MANAGEMENT LLC | $70.750.000 | 5.000.000 | 5,22% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $63.257.363 | 4.470.485 | 4,67% | Aktien |
| MARSHALL WACE, LLP | $61.250.852 | 4.328.682 | 4,52% | Aktien |
| ARK Investment Management LLC | $48.845.310 | 3.451.965 | 3,61% | Aktien |
| Point72 Asset Management, L.P. | $37.085.424 | 2.620.878 | 2,74% | Aktien |
| Logos Global Management LP | $31.837.500 | 2.250.000 | 2,35% | Aktien |
| Eagle Health Investments LP | $29.155.042 | 2.060.427 | 2,15% | Aktien |
| BANK OF AMERICA CORP /DE/ | $28.573.774 | 2.019.348 | 2,11% | Aktien |
| DAFNA Capital Management LLC | $28.469.121 | 2.011.952 | 2,10% | Aktien |
| Caption Management, LLC | $27.544.390 | 1.946.600 | 2,03% | Kaufoption |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $26.855.285 | 1.897.900 | 1,98% | Kaufoption |
| NEXTBio Capital Management LP | $25.126.990 | 1.775.759 | 1,85% | Aktien |
| UBS Group AG | $20.976.951 | 1.482.470 | 1,55% | Aktien |
| Aisling Capital Management LP | $20.267.554 | 1.432.336 | 1,50% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $20.261.229 | 1.431.889 | 1,50% | Aktien |
| Candriam S.C.A. | $18.013.686 | 1.274.278 | 1,33% | Aktien |
| Woodline Partners LP | $15.366.957 | 1.086.004 | 1,13% | Aktien |
| CITADEL ADVISORS LLC | $14.219.052 | 1.004.880 | 1,05% | Aktien |
| Jefferies Financial Group Inc. | $14.070.661 | 994.393 | 1,04% | Aktien |
| BlackRock, Inc. | $13.094.283 | 925.391 | 0,97% | Aktien |
| Trexquant Investment LP | $12.171.236 | 860.158 | 0,90% | Aktien |
| Kalehua Capital Management LLC | $11.598.642 | 819.692 | 0,86% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $10.909.466 | 770.987 | 0,81% | Aktien |
| Caption Management, LLC | $10.699.041 | 756.116 | 0,79% | Aktien |
| Eversept Partners, LP | $9.520.474 | 672.825 | 0,70% | Aktien |
| MORGAN STANLEY | $8.417.922 | 594.906 | 0,62% | Aktien |
| Propel Bio Management, LLC | $8.109.167 | 573.086 | 0,60% | Aktien |
| Creek Drive Management Group LLC | $8.093.800 | 572.000 | 0,60% | Aktien |
| Occam Crest Management LP | $7.739.000 | 710.000 | 0,57% | Aktien |
| CITADEL ADVISORS LLC | $7.567.420 | 534.800 | 0,56% | Kaufoption |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $7.140.090 | 504.600 | 0,53% | Verkaufsoption |
| SILVERARC CAPITAL MANAGEMENT, LLC | $7.122.855 | 503.382 | 0,53% | Aktien |
| JANE STREET GROUP, LLC | $7.102.310 | 501.930 | 0,52% | Aktien |
| Qube Research & Technologies Ltd | $7.070.415 | 499.676 | 0,52% | Aktien |
| Walleye Capital LLC | $6.893.385 | 487.165 | 0,51% | Aktien |
| Ensign Peak Advisors, Inc | $6.716.340 | 474.653 | 0,50% | Aktien |
| Blue Owl Capital Holdings LP | $6.367.500 | 450.000 | 0,47% | Aktien |
| AdvisorShares Investments LLC | $5.962.060 | 421.347 | 0,44% | Aktien |
| TWO SIGMA ADVISERS, LP | $5.909.850 | 856.500 | 0,44% | Aktien |
| GOLDMAN SACHS GROUP INC | $5.540.956 | 391.587 | 0,41% | Aktien |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | $5.438.567 | 384.351 | 0,40% | Aktien |
| HighVista Strategies LLC | $5.251.349 | 371.120 | 0,39% | Aktien |
| Legal & General Group Plc | $4.700.154 | 332.206 | 0,35% | Aktien |
| Sumitomo Mitsui Trust Group, Inc. | $4.573.407 | 323.209 | 0,34% | Aktien |
| Amova Asset Management Americas, Inc. | $4.517.334 | 319.472 | 0,33% | Aktien |
| Squadron Capital Management LLC | $4.315.750 | 305.000 | 0,32% | Kaufoption |
| Affinity Asset Advisors, LLC | $4.261.739 | 301.183 | 0,31% | Aktien |
Aktivisten & 5%+-Eigentümer 1 Beteiligung
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| AtaiBeckley Inc. | 17. Februar 2026 | 4,96% | Änderung | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 19 Insider · 6 Führungskräfte · 10 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Kabir Nath | Chief Executive Officer | 3. August 2026 F | 361.028 | 0 | 0 | $0 |
| Teri Loxam | Chief Financial Officer | 26. März 2026 A | 152.002 | 0 | 0 | $0 |
| Mary-Rose Hughes | Interim CFO | 1. Februar 2024 A | · | 0 | 0 | $0 |
| Michael Falvey | Chief Financial Officer | 2. Februar 2023 A | 22.500 | 0 | 0 | $0 |
| Guy Goodwin | Chief Medical Officer | 26. März 2026 A | 8.000 | 0 | 0 | $0 |
| Matthew A Owens | General Counsel & CLO | 1. Februar 2024 A | 43.340 | 0 | 0 | $0 |
| Robert Mcquade | Direktor | 27. Mai 2026 A | · | 0 | 0 | $0 |
| Kathleen Tregoning | Direktor | 27. Mai 2026 A | · | 0 | 0 | $0 |
| Daphne Karydas | Direktor | 27. Mai 2026 A | · | 0 | 0 | $0 |
| Justin D. Gover | Direktor | 27. Mai 2026 A | · | 0 | 0 | $0 |
| David Y Norton | Direktor | 27. Mai 2026 A | 20.356 | 0 | 0 | $0 |
| Wayne Joseph Riley | Direktor | 27. Mai 2026 A | · | 0 | 0 | $0 |
| Thomas Lonngren | Direktor | 12. Juni 2025 A | · | 0 | 0 | $0 |
| Annalisa Jenkins | Direktor | 12. Juni 2025 A | 19.480 | 0 | 0 | $0 |
| Linda Mcgoldrick | Direktor | 12. Juni 2025 A | · | 0 | 0 | $0 |
| Ekaterina Malievskaia | 10%-Eigentümer | 24. Oktober 2024 S | 3.155.122 | 0 | 0 | $0 |
| George Jay Goldsmith | 10%-Eigentümer | 24. Oktober 2024 S | 3.152.848 | 0 | 0 | $0 |
| Gino Santini | · | 27. Mai 2026 A | · | 0 | 0 | $0 |
| Jeffrey M Jonas | · | 27. Mai 2026 A | · | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 6 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| ARKG · ARK ETF Trust | 3,25% | 4.463.875 NS | 31. Juli 2026 | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 0,93% | 56.358 NS | 31. Juli 2026 | N-PORT |
| BBC · ETFis Series Trust I | 0,63% | 25.731 NS | 31. Juli 2026 | N-PORT |
| ESIM · Strategy Shares | 0,13% | 2.020 NS | 31. Juli 2026 | N-PORT |
| IBB · iShares Trust | 0,11% | 831.209 SH | 11. September 2026 | Täglich |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,11% | 9.493 SH | 2. Oktober 2026 | Täglich |
CMPS Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 24 Analysten
KAUF
Median-Ziel
$21.00
+76,5%
8 33,3%
Starker Kauf
14 58,3%
Kauf
2 8,3%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
16 Analysten · 2026-09-20Mittelwert-Ziel $23.75 +99,6%
← Unter allen Zielen
Aktueller Preis $11.90
Tief$13.00
Mittelwert$23.75
Hoch$65.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
FDA gewährt Rolling Review und CNPV-Bezeichnung für Compass Pathways (CMPS) zur Behandlung von TRD
Yahoo Finance · 5 Monate vor
Trump schickt Compass Pathways-Aktie auf Talfahrt, da er Psychedelika unterstützt. Sollten Sie CMPS hier kaufen?
Yahoo Finance · 5 Monate, 1 Woche vor
Warum die Aktie von Compass Pathways heute um 40 % gestiegen ist
Nasdaq · 5 Monate, 1 Woche vor
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 5, 2026